

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137366 A2

(51) International Patent Classification:

C07C 311/00 (2006.01) A61P 1/00 (2006.01)
C07F 9/6574 (2006.01) A61K 9/00 (2006.01)

(21) International Application Number:

PCT/US2024/061149

(22) International Filing Date:

19 December 2024 (19.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/612,879 20 December 2023 (20.12.2023) US

(71) Applicant: **TVARDI THERAPEUTICS, INC.** [US/US];
3 Sugar Creek Center Boulevard, Suite 525, Sugar Land,
TX 77478 (US).

(72) Inventors: **ALIBHAI, Imran**; c/o Tvardi Therapeutics,
Inc., 3 Sugar Creek Center Boulevard, Suite 525, Sugar
Land, TX 77478 (US). **DE ACHAVAL, Sofia**; c/o Tvardi
Therapeutics, Inc., 3 Sugar Creek Center Boulevard, Suite
525, Sugar Land, TX 77478 (US). **CHEN, Yixin**; c/o Tvardi


Therapeutics, Inc., 3 Sugar Creek Center Boulevard, Suite
525, Sugar Land, TX 77478 (US).

(74) Agent: **POULOS, Sabrina, D.** et al.; Goodwin Procter
LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: SOLID-STATE FORMS OF STAT3 INHIBITORS AND METHODS OF USE THEREOF



(I)




FIG. 1

(57) Abstract: Provided herein, in some embodiments, are solid-state forms of a compound represented by Formula (I), as free acid or base, or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprising one or more solid-state forms of a compound represented by Formula (I), as free acid or base, or a pharmaceutically acceptable salt or solvate thereof, and methods of use thereof.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*